

Funded Study: Treatment of canine multicentric lymphoma

Study Title: Assessing the efficacy and tolerability of daunomustine in dogs with multicentric lymphoma.

Purpose of Study/Background/Objectives: The purpose of this study is to evaluate the safety and anti-cancer activity of a novel chemotherapy, daunomustine in treatment naïve dogs with multicentric lymphoma.

Inclusion Criteria:

- Cytologic or histologic diagnosis of multicentric lymphoma for peripheral node with phenotype
- Treatment naïve including steroids
- Adequate organ function

Exclusion Criteria:

- Indolent or small cell lymphoma
- Previous chemotherapy or steroid therapy
- Liver values > 4x normal or elevated total bilirubin
- Bun and Creatinine > 1.5 normal

Eligibility Diagnostics:

- CBC, Chemistry Panel, U/A
- Cytology or histopathologic diagnosis with phenotype

Treatment/Protocol: The patient will receive up to 5 doses of daunomustine given every 21 days as IV bolus. The patient will have a CBC on day 7 at the U of IL and return for next treatment 2 weeks later. After the 5th dose the patient will return monthly for 4 visits, exam and lab work will be performed, then every 90 days for exam and lab work until progressive disease. Patients will be treated on an outpatient basis and go home each day.

Compensation: The study will cover all costs associated with therapy and diagnostics following patient eligibility. The owner is responsible for all costs associated with enrollment criteria. In the event of adverse events partial funding to cover these costs is available if treatment is pursued at the University of Illinois. Pet owners are responsible for treatment of unrelated medical conditions.

Contact Information: Please feel free to contact our Clinical Trials Coordinator, Rebecca Kamerer, at (217) 300-6453 or rmoss81@illinois.edu to refer a patient or for any additional information. Referring veterinarian and client calls are welcome.